Horizon Therapeutics PLC (OQ:HZNP)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: Connaught House
1St Floor, 1 Burlington Road
DUBLIN D04 C5Y6
Tel: N/A
Website: https://www.horizontherapeutics.com
IR: See website
<
Key People
Timothy P. Walbert
Chairman of the Board, President, Chief Executive Officer
Jeffrey D. Kent
Senior Vice President, Head of Medical Affairs and Outcomes Research
Paul W. Hoelscher
Chief Financial Officer, Executive Vice President
Irina P. Konstantinovsky
Chief Human Resource Officer, Executive Vice President
Barry J. Moze
Executive Vice President, Chief Administrative Officer
Brian K. Beeler
Executive Vice President, General Counsel
Geoffrey M. Curtis
Executive Vice President - Corporate Affairs, Chief Communications Officer
Michael A. DesJardin
Executive Vice President - Technical Operations and Corporate Quality
Vikram Karnani
Executive Vice President, Chief Commercial Officer
Andy Pasternak
Executive Vice President, Chief Business Officer
   
Business Overview
Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
Financial Overview
For the three months ended 31 March 2020, Horizon Therapeutics PLC revenues increased 27% to $355.9M. Net loss decreased 59% to $13.6M. Revenues reflect Orphan and Rheumatology segment increase of 32% to $245.4M, Inflammation segment increase of 17% to $110.5M, Rest of world segment increase of 63% to $1.9M. Lower net loss reflects Interest Expense, Net decrease of 37% to $17.3M (expense).
Employees: 1,185 as of Mar 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $11,142M as of Mar 31, 2020
Annual revenue (TTM): $1,376M as of Mar 31, 2020
EBITDA (TTM): $371.14M as of Mar 31, 2020
Net annual income (TTM): $592.29M as of Mar 31, 2020
Free cash flow (TTM): $172.56M as of Mar 31, 2020
Net Debt Last Fiscal Year: $603.72M as of Mar 31, 2020
Shares outstanding: 190,778,387 as of May 1, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization